179 related articles for article (PubMed ID: 29484684)
1. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.
Innocenti I; Rossi D; Trapè G; Autore F; Larocca LM; Gomes V; Cerri M; Falcucci P; Sica S; Gaidano G; Laurenti L
Hematol Oncol; 2018 Feb; ():. PubMed ID: 29484684
[TBL] [Abstract][Full Text] [Related]
2. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.
Kadri S; Lee J; Fitzpatrick C; Galanina N; Sukhanova M; Venkataraman G; Sharma S; Long B; Petras K; Theissen M; Ming M; Kobzev Y; Kang W; Guo A; Wang W; Niu N; Weiner H; Thirman M; Stock W; Smith SM; Nabhan C; Segal JP; Lu P; Wang YL
Blood Adv; 2017 May; 1(12):715-727. PubMed ID: 29296715
[TBL] [Abstract][Full Text] [Related]
3. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
4. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
5. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.
Miller CR; Ruppert AS; Heerema NA; Maddocks KJ; Labanowska J; Breidenbach H; Lozanski G; Zhao W; Gordon AL; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Blum KA; T Awan F; Rogers KA; Grever MR; Johnson AJ; Abruzzo LV; Hertlein EK; Blachly JS; Woyach JA; Byrd JC
Blood Adv; 2017 Aug; 1(19):1584-1588. PubMed ID: 29296799
[TBL] [Abstract][Full Text] [Related]
6. Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
Favini C; Talotta D; Almasri M; Andorno A; Rasi S; Adhinaveni R; Kogila S; Awikeh B; Schipani M; Boggione P; Mouhssine S; Ghanej J; Al Essa W; Mahmoud AM; Dondolin R; Alessa N; Margiotta Casaluci G; Boldorini R; Gattei V; Gaidano G; Moia R
Br J Haematol; 2022 Sep; 198(6):1016-1022. PubMed ID: 35829664
[TBL] [Abstract][Full Text] [Related]
7. SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.
Burke JM
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):427-435. PubMed ID: 35577753
[TBL] [Abstract][Full Text] [Related]
8. Revisiting Richter transformation in the era of novel CLL agents.
Petrackova A; Turcsanyi P; Papajik T; Kriegova E
Blood Rev; 2021 Sep; 49():100824. PubMed ID: 33775465
[TBL] [Abstract][Full Text] [Related]
9. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
[TBL] [Abstract][Full Text] [Related]
10. Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Woyach JA; Jones D; Jurczak W; Robak T; Illes A; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V
Blood; 2024 May; ():. PubMed ID: 38754046
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Iskierka-Jażdżewska E; Puła B; Szeremet A; Hus M; Gołos A; Hołojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Zaucha JM; Warzocha K; Jamroziak K
Adv Clin Exp Med; 2019 Aug; 28(8):1051-1057. PubMed ID: 31199879
[TBL] [Abstract][Full Text] [Related]
13. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
García-Barchino MJ; Sarasquete ME; Panizo C; Morscio J; Martinez A; Alcoceba M; Fresquet V; Gonzalez-Farre B; Paiva B; Young KH; Robles EF; Roa S; Celay J; Larrayoz M; Rossi D; Gaidano G; Montes-Moreno S; Piris MA; Balanzategui A; Jimenez C; Rodriguez I; Calasanz MJ; Larrayoz MJ; Segura V; Garcia-Muñoz R; Rabasa MP; Yi S; Li J; Zhang M; Xu-Monette ZY; Puig-Moron N; Orfao A; Böttcher S; Hernandez-Rivas JM; Miguel JS; Prosper F; Tousseyn T; Sagaert X; Gonzalez M; Martinez-Climent JA
J Pathol; 2018 May; 245(1):61-73. PubMed ID: 29464716
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
Albi E; Baldoni S; Aureli P; Dorillo E; Del Papa B; Ascani S; Di Ianni M; Falzetti F; Sportoletti P
Tumori; 2017 Nov; 103(Suppl. 1):e37-e40. PubMed ID: 28708231
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
[TBL] [Abstract][Full Text] [Related]
16. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; Arguiñano Pérez JM; Berruezo MJ; Oliveira A; Hernández-Rivas JÁ; García Malo MD; Medina Á; García Martin P; Osorio S; Baltasar P; Fernández-Zarzoso M; Marco F; Vidal Manceñido MJ; Smucler Simonovich A; López Rubio M; Jarque I; Suarez A; Fernández Álvarez R; Lancharro Anchel A; Ríos E; Losada Castillo MDC; Pérez Persona E; García Muñoz R; Ramos R; Yáñez L; Bello JL; Loriente C; Acha D; Villanueva M
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e985-e999. PubMed ID: 34511320
[TBL] [Abstract][Full Text] [Related]
17. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
Woyach JA; Ghia P; Byrd JC; Ahn IE; Moreno C; O'Brien SM; Jones D; Cheung LWK; Chong E; Kwei K; Dean JP; James DF; Wiestner A
Clin Cancer Res; 2023 Aug; 29(16):3065-3073. PubMed ID: 37314786
[TBL] [Abstract][Full Text] [Related]
18. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
Jamroziak K; Tadmor T; Robak T; Polliack A
Leuk Lymphoma; 2015 Jul; 56(7):1949-58. PubMed ID: 25356923
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]